KCT0009093招募中Unknown
A phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab versus locoregional therapy with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria (REPLACE)
Inje University Haeundae Paik Hospital0 个研究点目标入组 496 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 496
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18(Year) 至 75(Year)（—）
- 性别
- All
入选标准
- •1. Signed and dated PICF obtained prior to any protocol related procedure that is not part of standard patient care.
- •2. Patient is = 18 years-old at the time of PICF signature (or the legal age of consent in the jurisdiction in which the trial is taking place).
- •3. Confirmed diagnosis of HCC based on:
- •? Histopathological findings from tumor tissue, and/or ? Diagnostic imaging on dynamic CT or MRI according to AASLD criteria (https://www.aasld.org/publications/practiceguidelines).
- •4. Intermediate-stage HCC, defined as follows:
- •? Multinodular HCC (more than 3 tumors in the liver or 1 to 3 tumors with at least 1 that is larger than 5 cm), localized to the liver.
- •? No evidence of MVI or EHS on the screening or any prior imaging.
- •? Not amenable to curative treatment (e.g., surgery or transplantation or curative ablation).
- •? Liver function status Child-Pugh Class A. Child-Pugh status should be calculated based on clinical findings and laboratory results during the screening period.
- •? ECOG PS 0 or 1 at screening.
- •? ALBI grade 1 or 2 at screening.
- •5. Beyond up-to-7 criteria, defined as an HCC exceeding the up-to-7 criteria (Up-to-7 criteria = largest tumor diameter (cm) + number of tumors =7).
- •6. Disease amenable to TACE or TARE and no contraindication to intra-arterial treatment. All liver disease should be able to be controlled with the protocol-required TACE/TARE procedures, in the opinion of the Investigator.
- •7. Measurable disease by CT or MRI as per RECIST 1.1 criteria based on radiographic tumor assessment performed = 28 days prior to randomization.
- •8. No prior systemic or locoregional therapy for HCC, with the exception of patients previously treated with resection and/or ablation that meet ALL the following criteria:
- •? Prior resection/ablation (latest procedure prior to enrollment) achieved complete response.
- •? Time from completion of prior resection/ablation (latest procedure prior to enrollment) until diagnosis of recurrence is = 6 months (i.e., = 180 days) ? Recurrence diagnosed = 1 year (i.e., = 365 days) before randomization date.
- •? HCC recurrence comprises at least 2 untreated lesions (i.e., not previously ablated/resected) having each = 10 mm in longest diameter and showing intratumoral arterial enhancement, according to radiographic tumor assessment performed = 28 days prior to randomization.
- •9. Adequate hematologic and organ function as assessed by the following laboratory tests performed = 7 days before randomization:
- •? Hematological:
- •? Platelet count = 75,000 /mm 3
- •? Hemoglobin = 9.0 g/dL
- •? Absolute neutrophil count = 1,500 /µL
- •Note: Patients who received blood products during screening for the purposes of meeting eligibility criteria, are not eligible.
- •? Hepatic/Pancreatic:
- •? Total bilirubin = 2.0 × the upper limit of normal (ULN). Total bilirubin (=3 x ULN) is allowed if Gilbert’s syndrome is documented.
- •? Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 5.0 x ULN ? Lipase = 2 x ULN ? Amylase = 2 x ULN ? Coagulation:
- •? International normalized ratio (INR) < 2.3 and activated partial thromboplastin time (aPTT) < 1.5 x ULN unless receiving treatment with therapeutic anticoagulation ? Renal:
- •? Serum creatinine ??1.5 x ULN or calculated creatinine clearance ? 40 mL/min (using the Cockcroft-Gault formula)
- •10. Patients with hepatitis B virus (HBV) infection will be eligible if they meet the following criteria (according to testing done at screening, unless pre-trial results are
排除标准
- •1. No measurable tumor of a diffuse infiltrative HCC type.
- •2. Fibrolamellar HCC, sarcomatoid HCC or mixed hepatocellular/cholangiocarcinoma subtypes.
- •3. Clinically meaningful ascites, defined as ascites requiring nonpharmacologic intervention (e.g., paracentesis) to maintain symptomatic control, = 6 months prior to randomization. Patients with ascites that have required pharmacologic intervention (e.g., diuretics) and who have been on stable doses of diuretics for ascites for greater than or equal to 2 months are eligible.
- •4. Prior treatment with regorafenib, a PD-1, PD-L1/PD-L2, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
- •5. Previous treatment with a live replication-competent vaccine = 30 days prior to the planned date of trial treatment start.
- •6. Treatment with a strong CYP3A4 inducer or strong CYP3A4 inhibitor = 14 days prior to the planned date of trial treatment start (see section 5.6.6).
- •7. Concurrent participation in another clinical trial, unless it is: (a) an observational (non-interventional) clinical trial, or (b) the follow-up period of an interventional trial and patient did not receive an investigational agent/device = 28 days before randomization (or = 5 half-lives of the drug, whichever is longer).
- •8. Known hypersensitivity to any of the trial drugs or their formulation components.
- •9. Major surgical procedure, open biopsy or significant traumatic injury = 28 days prior to randomization. Patients must have recovered adequately from the toxicity and/or complications from the intervention before randomization.
- •10. Active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids.
- •These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus, connective tissue diseases, scleroderma, inflammatory bowel disease, Crohn’s, ulcerative colitis, hepatitis; and patients with a history of TEN, SJS, or phospholipid syndrome.
- •Note: Patients with the following diseases are not excluded:
- •? Controlled Type I diabetes ? Hypothyroidism (provided it is managed with hormone replacement therapy only) ? Celiac disease controlled by diet alone ? Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, alopecia) ? Any other disease that is not expected to recur in the absence of external triggering factors
- •11. Requirement of systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medications = 14 days prior to randomization.
- •Note: Patients who are currently or have previously been on any of the following steroid regimens are not excluded:
- •? Adrenal replacement steroid (dose = 10 mg daily of prednisone or equivalent) ? Topical, ocular, intra-articular, intranasal, or inhaled corticosteroid with minimal systemic absorption ? Short course (= 7 days) of corticosteroid prescribed prophylactically (e.g., for contrast dye allergy) or for the treatment of a nonautoimmune condition (e.g., delayed-type hypersensitivity reaction caused by contact allergen)
- •12. Uncontrolled diabetes or > Grade 1 laboratory test abnormalit
研究者
相似试验
进行中（未招募）
1 期
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib withendocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancerhormone receptor-positive, HER2-negative, early breast cancerMedDRA version: 20.0Level: LLTClassification code 10006203Term: Breast cancer stage unspecifiedSystem Organ Class: 100000004864MedDRA version: 20.1Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864EUCTR2018-002998-21-FRovartis Pharma AG4,000
进行中（未招募）
1 期
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib withendocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancerhormone receptor-positive, HER2-negative, early breast cancerMedDRA version: 20.0Level: LLTClassification code 10006203Term: Breast cancer stage unspecifiedSystem Organ Class: 100000004864MedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864EUCTR2018-002998-21-BEovartis Pharma AG5,000
招募中
1 期
Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7.Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.MedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104CTIS2022-501969-42-00Translational Research In Oncology597
招募中
3 期
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer2023-510357-42-00Novartis Pharma AG2,394
进行中（未招募）
1 期
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib withendocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancerhormone receptor-positive, HER2-negative, early breast cancerMedDRA version: 20.0Level: LLTClassification code 10006203Term: Breast cancer stage unspecifiedSystem Organ Class: 100000004864MedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864EUCTR2018-002998-21-PLovartis Pharma AG5,000